BLOODPAC members representing drug and assay development will discuss the value of strategic collaborations to advance the implementation of MRD and its validation as an early endpoint in solid tumors. This panel will be part of the 2023 Molecular and Precision Medicine Tri-Con. Panelists include Angela Silvestro (Director, Companion Diagnostics, GSK), Asaf Zviran (Founder and CEO, C2i Genomics), Duane Hassane (VP, Tempus Labs), and Minetta C. Liu (CMO, Natera).